Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
Abstract
:Simple Summary
Abstract
1. Introduction
2. Physicochemical Properties of DCX
3. Pharmacokinetics (PK)
3.1. Mechanism of Action of DCX in Lung Cancer
3.2. DCX Resistance
4. Drug Delivery for DCX
4.1. Route of DCX Delivery
4.2. DCX Formulations
4.2.1. Taxotere® Formulations
4.2.2. DCX-Loaded Nanoparticles (NPs)
4.2.3. Solid Lipid Nanoparticles (SLNs)
4.2.4. Liposomes
4.2.5. Polymeric Nanoparticles (PNPs)
4.2.6. Polymeric Micelles (PMs)
4.2.7. Lipid-Polymer Hybrid Nanoparticles (LPHNPs)
4.3. Inorganic Nanoparticles
4.3.1. Carbon Nanotubes (CNTs)
4.3.2. Mesoporous Silica Nanoparticles (MSNs)
4.3.3. Gold Nanoparticles (AuNPs)
5. Perspective
6. Conclusions
Funding
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Denis, J.N.; Greene, A.E.; Guenard, D.; Gueritte-Voegelein, F.; Mangatal, L.; Potier, P. Highly efficient, practical approach to natural taxol. J. Am. Chem. Soc. 1988, 110, 5917–5919. [Google Scholar] [CrossRef]
- Zhao, P.; Astruc, D. Docetaxel Nanotechnology in Anticancer Therapy. ChemMedChem 2012, 7, 952–972. [Google Scholar] [CrossRef] [PubMed]
- Da Silva, G.H.; Fernandes, M.A.; Trevizan, L.N.F.; de Lima, F.T.; Eloy, J.O.; Chorilli, M. A Critical Review of Properties and Analytical Methods for the Determination of Docetaxel in Biological and Pharmaceutical Matrices. Crit. Rev. Anal. Chem. 2018, 48, 517–527. [Google Scholar] [CrossRef]
- Baker, J.; Ajani, J.; Scotté, F.; Winther, D.; Martin, M.; Aapro, M.S.; von Minckwitz, G. Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs. 2009, 13, 49–59. [Google Scholar] [CrossRef]
- Herbst, R.S.; Khuri, F.R. Mode of action of docetaxel-A basis for combination with novel anticancer agents. Cancer Treat. Rev. 2003, 29, 407–415. [Google Scholar] [CrossRef]
- Takimoto, C.H.; Beeram, M. Microtubule Stabilizing Agents in Clinical Oncology. In The Role of Microtubules in Cell Biology, Neurobiology, and Oncology; Humana Press: Totowa, NJ, USA, 2009; pp. 395–419. [Google Scholar]
- Hitt, R.; Rodriguez, C. Docetaxel, 3rd ed.; Schwab, M., Ed.; Springer Berlin Heidelberg: Berlin/Heidelberg, Germany, 2011; pp. 395–419. [Google Scholar]
- Saloustros, E.; Georgoulias, V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev. Anticancer. Ther. 2008, 8, 1207–1222. [Google Scholar] [CrossRef]
- Loiseau, A.; Boudon, J.; Oudot, A.; Moreau, M.; Boidot, R.; Chassagnon, R.; Saïd, N.M.; Roux, S.; Mirjolet, C.; Millot, N. Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors. Cancers 2019, 11, 1962. [Google Scholar] [CrossRef] [Green Version]
- Gaio, E.; Conte, C.; Esposito, D.; Reddi, E.; Quaglia, F.; Moret, F. CD44 Targeting Mediated by Polymeric Nanoparticles and Combination of Chlorine TPCS(2a)-PDT and Docetaxel-Chemotherapy for Efficient Killing of Breast Differentiated and Stem Cancer Cells In Vitro. Cancers 2020, 12, 278. [Google Scholar] [CrossRef] [Green Version]
- Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2012, 64, 4–17. [Google Scholar] [CrossRef]
- Thanki, K.; Gangwal, R.P.; Sangamwar, A.T.; Jain, S. Oral delivery of anticancer drugs: Challenges and opportunities. J. Control. Release 2013, 170, 15–40. [Google Scholar] [CrossRef] [PubMed]
- Sohail, M.F.; Rehman, M.; Sarwar, H.S.; Naveed, S.; Salman, O.; Bukhari, N.I.; Hussain, I.; Webster, T.J.; Shahnaz, G. Advancements in the Oral Delivery of Docetaxel: Challenges, Current State-of-the-Art and Future Trends. Int. J. Nanomed. 2018, 13, 3145–3161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Clarke, S.J.; Rivory, L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharm. 1999, 36, 99–114. [Google Scholar] [CrossRef] [PubMed]
- Kenmotsu, H.; Tanigawara, Y. Pharmacokinetics, Dynamics and Toxicity of Docetaxel: Why the Japanese dose Differs from the Western Dose. Cancer Sci. 2015, 106, 497–504. [Google Scholar] [CrossRef]
- Baker, S.D.; Sparreboom, A.; Verweij, J. Clinical Pharmacokinetics of Docetaxel: Recent Developments. Clin. Pharm. 2006, 45, 235–252. [Google Scholar] [CrossRef]
- Shou, M.; Martinet, M.; Korzekwa, K.R.; Krausz, K.W.; Gonzalez, F.J.; Gelboin, H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998, 8, 391–401. [Google Scholar] [CrossRef]
- Loos, W.J.; Baker, S.D.; Verweij, J.; Boonstra, J.G.; Sparreboom, A. Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins. Clin. Pharmacol. Ther. 2003, 74, 364–371. [Google Scholar] [CrossRef]
- Guitton, J.; Cohen, S.; Tranchand, B.; Vignal, B.; Droz, J.P.; Guillaumont, M.; Manchon, M.; Freyer, G. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 2419–2426. [Google Scholar] [CrossRef]
- Condoluci, A.; Mazzara, C.; Zoccoli, A.; Pezzuto, A.; Tonini, G. Impact of smoking on lung cancer treatment effectiveness: A review. Future Oncol. 2016, 12, 2149–2161. [Google Scholar] [CrossRef]
- De Graan, A.-J.M.; Loos, W.J.; Friberg, L.E.; Baker, S.D.; van der Bol, J.M.; van Doorn, L.; Wiemer, E.A.C.; van der Holt, B.; Verweij, J.; Mathijssen, R.H.J. Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy. Clin. Cancer Res. 2012, 18, 4425. [Google Scholar] [CrossRef] [Green Version]
- Comer, A.M.; Goa, K.L. Docetaxel. In A Review of Its Use in Non-Small cell Lung Cancer. Drugs Aging 2000, 17, 53–80. [Google Scholar] [CrossRef] [PubMed]
- Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind. Ann. Oncol. 1994, 5, 495–505. [Google Scholar] [CrossRef]
- Hardwick, J.M.; Soane, L. Multiple functions of BCL-2 family proteins. Cold Spring Harb. Perspect. Biol. 2013, 5, a008722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Inoue, Y.; Gika, M.; Abiko, T.; Oyama, T.; Saitoh, Y.; Yamazaki, H.; Nakamura, M.; Abe, Y.; Kawamura, M.; Kobayashi, K. Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol. Rep. 2005, 13, 259–264. [Google Scholar] [PubMed]
- Savry, A.; Carre, M.; Berges, R.; Rovini, A.; Pobel, I.; Chacon, C.; Braguer, D.; Bourgarel-Rey, V. Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: Implications for cancer treatment. Neoplasia 2013, 15, 49–60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hotchkiss, K.A.; Ashton, A.W.; Mahmood, R.; Russell, R.G.; Sparano, J.A.; Schwartz, E.L. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by Docetaxel (Taxotere): Association with Impaired Repositioning of the Microtubule Organizing Center. Mol. Cancer Ther. 2002, 1, 1191–1200. [Google Scholar]
- Wu, H.; Xin, Y.; Zhao, J.; Sun, D.; Li, W.; Hu, Y.; Wang, S. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother. Pharmacol. 2011, 68, 879–887. [Google Scholar] [CrossRef]
- Fitzpatrick, F.A.; Wheeler, R. The immunopharmacology of paclitaxel (Taxol®), docetaxel (Taxotere®), and related agents. Int. Immunopharmacol. 2003, 3, 1699–1714. [Google Scholar] [CrossRef]
- Chang, A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71, 3–10. [Google Scholar] [CrossRef]
- Hayashi, Y.; Kuriyama, H.; Umezu, H.; Tanaka, J.; Yoshimasu, T.; Furukawa, T.; Tanaka, H.; Kagamu, H.; Gejyo, F.; Yoshizawa, H. Class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern. Med. 2009, 48, 203–208. [Google Scholar] [CrossRef] [Green Version]
- Alamgeer, M.; Peacock, C.D.; Matsui, W.; Ganju, V.; Watkins, D.N. Cancer Stem cells in Lung Cancer: Evidence and Controversies. Respirology 2013, 18, 757–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Campbell, L.; Abulrob, A.-N.G.; Kandalaft, L.E.; Plummer, S.; Hollins, A.J.; Gibbs, A.; Gumbleton, M. Constitutive Expression of P-Glycoprotein in Normal Lung Alveolar Epithelium and Functionality in Primary Alveolar Epithelial Cultures. J. Pharmacol. Exp. Ther. 2003, 304, 441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shirakawa, K.; Takara, K.; Tanigawara, Y.; Aoyama, N.; Kasuga, M.; Komada, F.; Sakaeda, T.; Okumura, K. Interaction of docetaxel (‘Taxotere’) with human P-glycoprotein. Jpn. J. Cancer Res. 1999, 90, 1380–1386. [Google Scholar] [CrossRef]
- Merk, J.; Rolff, J.; Dorn, C.; Leschber, G.; Fichtner, I. Chemoresistance in non-small-cell lung cancer: Can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? Eur. J. Cardio Thorac. Surgery 2011, 40, e29–e33. [Google Scholar] [CrossRef]
- Chiou, J.F.; Liang, J.A.; Hsu, W.H.; Wang, J.J.; Ho, S.T.; Kao, A. Comparing the Relationship of Taxol-Based Chemotherapy Response with P-glycoprotein and Lung Resistance-Related Protein Expression in Non-Small Cell Lung Cancer. Lung 2003, 181, 267–273. [Google Scholar] [CrossRef] [PubMed]
- Quail, D.F.; Joyce, J.A. Microenvironmental Regulation of Tumor Progression and Metastasis. Nat. Med. 2013, 19, 1423–1437. [Google Scholar] [CrossRef] [PubMed]
- Son, B.; Lee, S.; Youn, H.S.; Kim, E.G.; Kim, W.; Youn, B.H. The role of tumor microenvironment in therapeutic resistance. Oncotarget 2017, 8, 3933–3945. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Babu, A.; Templeton, A.K.; Munshi, A.; Ramesh, R. Nanoparticle-Based drug Delivery for Therapy of Lung Cancer: Progress and Challenges. J. Nanomater. 2013, 2013. [Google Scholar] [CrossRef] [Green Version]
- Koolen, S.L.W.; Beijnen, J.H.; Schellens, J.H.M. Intravenous-to-Oral Switch in Anticancer Chemotherapy: A Focus on Docetaxel and Paclitaxel. Clin. Pharmacol. Ther. 2010, 87, 126–129. [Google Scholar] [CrossRef]
- Moreno-Sastre, M.; Pastor, M.; Salomon, C.J.; Esquisabel, A.; Pedraz, J.L. Pulmonary Drug Delivery: A Review on Nanocarriers for Antibacterial Chemotherapy. J. Antimicrob. Chemother. 2015, 70, 2945–2955. [Google Scholar] [CrossRef] [Green Version]
- Mangal, S.; Gao, W.; Li, T.; Zhou, Q.T. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: Challenges and opportunities. Acta Pharmacol. Sin. 2017, 38, 782–797. [Google Scholar] [CrossRef] [PubMed]
- Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83, 761–769. [Google Scholar] [CrossRef] [PubMed]
- Labiris, N.R.; Dolovich, M.B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56, 600–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hart, M.; Acott, S. Physical and chemical stability of Taxotere (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage. Ecancermedicalscience 2010, 4, 202. [Google Scholar] [PubMed]
- Tang, X.; Wang, G.; Shi, R.; Jiang, K.; Meng, L.; Ren, H.; Wu, J.; Hu, Y. Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles. Drug Deliv. 2016, 23, 2686–2696. [Google Scholar] [CrossRef]
- Ho, M.Y.; Mackey, J.R. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag. Res. 2014, 6, 253–259. [Google Scholar] [CrossRef]
- Picard, M.; Castells, M.C. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review. Clin. Rev. Allergy Immunol. 2015, 49, 177–191. [Google Scholar] [CrossRef]
- De, T.; Veith, J.; Bernacki, R.J.; Soon-Shiong, P.; Desai, N. Nab-028, a nanoparticle albumin-bound novel taxane, shows improved efficacy and lower toxicity over the tween formulation (Tween-028). Cancer Res. 2005, 65 (Suppl. 9), 335. [Google Scholar]
- Van Zuylen, L.; Verweij, J.; Sparreboom, A. Role of formulation vehicles in taxane pharmacology. Investig. New Drugs 2001, 19, 125–141. [Google Scholar] [CrossRef]
- Ten Tije, A.J.; Verweij, J.; Loos, W.J.; Sparreboom, A. Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy. Clin Pharmacokinet. 2003, 42, 665–685. [Google Scholar] [CrossRef] [Green Version]
- Sanna, V.; Roggio, A.M.; Posadino, A.M.; Cossu, A.; Marceddu, S.; Mariani, A.; Alzari, V.; Uzzau, S.; Pintus, G.; Sechi, M. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: Formulation, characterization, and cytotoxicity studies. Nanoscale Res. Lett. 2011, 6, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine in Cancer Therapy: Challenges, Opportunities, and Clinical Applications. J. Control. Release 2015, 200, 138–157. [Google Scholar] [CrossRef] [PubMed]
- Tran, S.; DeGiovanni, P.-J.; Piel, B.; Rai, P. Cancer nanomedicine: A review of recent success in drug delivery. Clin. Transl. Med. 2017, 6, 44. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ekambaram, P.; Sathali, A.H.; Priyanka, K. Solid lipid nanoparticles- A review. Int. J. Appl. Pharm. 2012, 2, 80–102. [Google Scholar]
- Shah, M.; Agrawal, Y.K.; Garala, K.; Ramkishan, A. Solid lipid nanoparticles of a water soluble drug, ciprofloxacin hydrochloride. Indian J. Pharm. Sci. 2012, 74, 434–442. [Google Scholar] [CrossRef] [Green Version]
- Mishra, V.; Bansal, K.K.; Verma, A.; Yadav, N.; Thakur, S.; Sudhakar, K.; Rosenholm, J.M. Solid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems. Pharmaceutics 2018, 10, 191. [Google Scholar] [CrossRef] [Green Version]
- Duan, Y.; Dhar, A.; Patel, C.; Khimani, M.; Neogi, S.; Sharma, P.; Siva Kumar, N.; Vekariya, R.L. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Adv. 2020, 10, 26777–26791. [Google Scholar] [CrossRef]
- Ganesan, P.; Narayanasamy, D. Lipid Nanoparticles: Different Preparation Techniques, Characterization, Hurdles, and Strategies for the Production of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Oral Drug Delivery. Sustain. Chem. Pharm. 2017, 6, 37–56. [Google Scholar] [CrossRef]
- Mehnert, W.; Mäder, K. Solid Lipid Nanoparticles: Production, Characterization and Applications. Adv. Drug Deliv. Rev. 2012, 64, 83–101. [Google Scholar] [CrossRef]
- Gordillo-Galeano, A.; Mora-Huertas, C.E. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Eur. J. Pharm. Biopharm. 2018, 133, 285–308. [Google Scholar] [CrossRef]
- Gref, R.; Domb, A.; Quellec, P.; Blunk, T.; Müller, R.H.; Verbavatz, J.M.; Langer, R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16, 215–233. [Google Scholar] [CrossRef] [Green Version]
- Moghimi, S.M.; Szebeni, J. Stealth Liposomes and Long Circulating Nanoparticles: Critical Issues in Pharmacokinetics, Opsonization and Protein-Binding Properties. Prog. Lipid Res. 2003, 42, 463–478. [Google Scholar] [CrossRef]
- Naguib, Y.W.; Rodriguez, B.L.; Li, X.; Hursting, S.D.; Williams, R.O.; Cui, Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: In vitro and in vivo evaluation. Mol. Pharm. 2014, 11, 1239–1249. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Wang, L.; Li, N.; Liu, Y.; Su, H. Combination lung cancer chemotherapy: Design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed. Pharmacother. 2017, 95, 548–555. [Google Scholar] [CrossRef] [PubMed]
- Xu, Z.; Mei, J.; Tan, Y. Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt. Int. J. Oncol. 2017, 50, 93–100. [Google Scholar] [CrossRef]
- Anwar, A.; Ovais, M.; Khan, A.; Raza, A. Docetaxel-Loaded Solid Lipid Nanoparticles: A Novel Drug Delivery System. IET Nanobiotechnol. 2017, 11, 621–629. [Google Scholar]
- Sastri, K.T.; Radha, G.V.; Pidikiti, S.; Vajjhala, P. Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies. J. Appl. Pharm. Sci. 2020, 10, 126–141. [Google Scholar]
- Deshpande, P.P.; Biswas, S.; Torchilin, V.P. Current Trends in the Use of Liposomes for Tumor Targeting. Nanomedicine 2013, 8, 1509–1528. [Google Scholar] [CrossRef] [Green Version]
- He, H.; Lu, Y.; Qi, J.; Zhu, Q.; Chen, Z.; Wu, W. Adapting Liposomes for Oral Drug Delivery. Acta Pharm. Sin. B. 2019, 9, 36–48. [Google Scholar] [CrossRef]
- Bangham, A.D.; Standish, M.M.; Watkins, J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13, 238-IN27. [Google Scholar] [CrossRef]
- Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett. 2013, 8, 102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lasch, J.; Weissig, V.; Brandl, M. Preparation of Liposomes. Liposomes A Pract. Approach 2003, 2, 24–25. [Google Scholar]
- Patel, J. Liposomal doxorubicin: Doxil®. J. Oncol. Pharm. Pract. 1996, 2, 201–210. [Google Scholar] [CrossRef]
- Pauli, G.; Tang, W.-L.; Li, S.-D. Development and Characterization of the Solvent-Assisted Active Loading Technology (SALT) for Liposomal Loading of Poorly Water-Soluble Compounds. Pharmaceutics 2019, 11, 465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Motamarry, A.; Asemani, D.; Haemmerich, D. Thermosensitive Liposomes. Liposome. Rijeka InTech. 2017, 187–212. [Google Scholar]
- Golombek, S.K.; May, J.N.; Theek, B.; Appold, L.; Drude, N.; Kiessling, F.; Lammers, T. Tumor Targeting via EPR: Strategies to Enhance Patient Responses. Adv. Drug Deliv. Rev. 2018, 130, 17–38. [Google Scholar] [CrossRef] [PubMed]
- Ren, H.; He, Y.; Liang, J.; Cheng, Z.; Zhang, M.; Zhu, Y.; Hong, C.; Qin, J.; Xu, X.; Wang, J. Role of Liposome Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting Therapy. ACS Appl. Mater. Interfaces 2019, 11, 20304–20315. [Google Scholar] [CrossRef] [PubMed]
- Wei, X.-Q.; Ba, K. Construction a Long-Circulating Delivery System of Liposomal Curcumin by Coating Albumin. ACS Omega 2020, 5, 16502–16509. [Google Scholar] [CrossRef] [PubMed]
- Chauhan, T.; Rani, V.; Sahu, B.; Sharma, A.; Chand Kheruka, S.; Gambhir, S.; Dube, V.; Aggarwal, L.M.; Chawla, R. Negatively charged liposomes of sertraline hydrochloride: Formulation, characterization and pharmacokinetic studies. J. Drug Deliv. Sci. Technol. 2020, 58, 101780. [Google Scholar] [CrossRef]
- Maja, L.; Željko, K.; Mateja, P. Sustainable technologies for liposome preparation. J. Supercrit. Fluids 2020, 165, 104984. [Google Scholar] [CrossRef]
- Li, M.; Du, C.; Guo, N.; Teng, Y.; Meng, X.; Sun, H.; Li, S.; Yu, P.; Galons, H. Composition design and medical application of liposomes. Eur. J. Med. Chem. 2019, 164, 640–653. [Google Scholar] [CrossRef] [PubMed]
- Pereira, S.; Egbu, R.; Jannati, G.; Al-Jamal, W.T. Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int. J. Pharm. 2016, 514, 150–159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arthur, P.; Patel, N.; Surapaneni, S.K.; Mondal, A.; Gebeyehu, A.; Bagde, A.; Kutlehria, S.; Nottingham, E.; Singh, M. Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts. Toxicol. Appl. Pharmacol. 2020, 401, 115112. [Google Scholar] [CrossRef] [PubMed]
- Pallasch, F.B.; Schumacher, U. Angiotensin Inhibition, TGF-β and EMT in Cancer. Cancers 2020, 12, 2785. [Google Scholar] [CrossRef] [PubMed]
- Saito, A.; Horie, M.; Nagase, T. TGF-β Signaling in Lung Health and Disease. Int. J. Mol. Sci. 2018, 19, 2460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gordon, S.R.; Maute, R.L.; Dulken, B.W.; Hutter, G.; George, B.M.; McCracken, M.N.; Gupta, R.; Tsai, J.M.; Sinha, R.; Corey, D. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017, 545, 495–499. [Google Scholar] [CrossRef] [PubMed]
- Ma, J.; Zhuang, H.; Zhuang, Z.; Lu, Y.; Xia, R.; Gan, L.; Wu, Y. Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting. Artif. Cells Nanomed. Biotechnol. 2018, 46, 1864–1871. [Google Scholar] [CrossRef] [Green Version]
- Glumac, P.M.; LeBeau, A.M. The role of CD133 in cancer: A concise review. Clin. Transl. Med. 2018, 7, 18. [Google Scholar] [CrossRef]
- Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di Virgilio, A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15, 504–514. [Google Scholar] [CrossRef]
- Zhai, G.; Wu, J.; Xiang, G.; Mao, W.; Yu, B.; Li, H.; Piao, L.; Lee, L.J.; Lee, R.J. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. J. Nanosci. Nanotechnol. 2009, 9, 2155–2161. [Google Scholar] [CrossRef] [Green Version]
- Zhu, X.; Kong, Y.; Liu, Q.; Lu, Y.; Xing, H.; Lu, X.; Yang, Y.; Xu, J.; Li, N.; Zhao, D.; et al. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy. Pulm. Pharmacol. Ther. 2019, 55, 50–61. [Google Scholar] [CrossRef] [PubMed]
- Shi, H.; Guo, J.; Li, C.; Wang, Z. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des. Devel. Ther. 2015, 9, 4989–4996. [Google Scholar] [PubMed] [Green Version]
- Mehendale, P.; Athawale, R. Dry Powder Inhaler of a Cytotoxic Agent, a New Avenue as Drug Delivery for the Lung Cancer. Available online: https://ssrn.com/abstract=3528249 (accessed on 30 October 2020).
- Langer, R.; Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263, 797–800. [Google Scholar] [CrossRef] [PubMed]
- Rao, J.P.; Geckeler, K.E. Polymer Nanoparticles: Preparation Techniques and Size-Control Parameters. Prog. Polym. Sci. 2011, 36, 887–913. [Google Scholar] [CrossRef]
- Bamrungsap, S.; Zhao, Z.; Chen, T.; Wang, L.; Li, C.; Fu, T.; Tan, W. Nanotechnology in Therapeutics: A Focus on Nanoparticles as a Drug Delivery System. Nanomedicine 2012, 7, 1253–1271. [Google Scholar] [CrossRef]
- Ali, I.; Alsehli, M.; Scotti, L.; Tullius Scotti, M.; Tsai, S.-T.; Yu, R.-S.; Hsieh, M.F.; Chen, J.-C. Progress in Polymeric Nano-Medicines for Theranostic Cancer Treatment. Polymers 2020, 12, 598. [Google Scholar] [CrossRef] [Green Version]
- Song, R.; Murphy, M.; Li, C.; Ting, K.; Soo, C.; Zheng, Z. Current Development of Biodegradable Polymeric Materials for Biomedical Applications. Drug Des. Devel. Ther. 2018, 12, 3117–3145. [Google Scholar] [CrossRef] [Green Version]
- Maitz, M.F. Applications of synthetic polymers in clinical medicine. Biosurface Biotribol. 2015, 1, 161–176. [Google Scholar] [CrossRef] [Green Version]
- Müller, R.H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47, 3–19. [Google Scholar] [CrossRef]
- Hu, C.M.J.; Aryal, S.; Zhang, L. Nanoparticle-Assisted Combination Therapies for Effective Cancer Treatment. Ther. Deliv. 2010, 1, 323–334. [Google Scholar] [CrossRef]
- Karlsson, J.; Vaughan, H.J.; Green, J.J. Biodegradable polymeric nanoparticles for therapeutic cancer treatments. Annu. Rev. Chem. Biomol. Eng. 2018, 9, 105–127. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Zhao, L.; Kang, Y.; He, Z.; Xiong, F.; Ling, X.; Wu, J. Significant suppression of non-small-cell lung cancer by hydrophobic poly(ester amide) nanoparticles with high docetaxel loading. Front. Pharmacol. 2018, 9, 118. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Yang, F.; Liao, Y.; Li, L.; Zhao, G.; Zhang, L. Docetaxel-Loaded Cholesterol-PEG Co-Modified Poly (n-Butyl) Cyanoacrylate Nanoparticles for Antitumor Drug Pulmonary Delivery: Preparation, Characterization, and in vivo Evaluation. Int. J. Nanomed. 2020, 15, 5361–5376. [Google Scholar] [CrossRef] [PubMed]
- Patel, J.; Amrutiya, J.; Bhatt, P.; Javia, A.; Jain, M.; Misra, A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J. Microencapsul. 2018, 35, 204–217. [Google Scholar] [CrossRef]
- Zhang, F.; Yu, Y.; Xing, L.; Chen, M. Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure. Int. J. Clin. Exp. Med. 2015, 8, 16140–16148. [Google Scholar]
- Chi, C.; Li, F.; Liu, H.; Feng, S.; Zhang, Y.; Zhou, D.; Zhang, R. Docetaxel-loaded biomimetic nanoparticles for targeted lung cancer therapy in vivo. J. Nanoparticle Res. 2019, 21, 144. [Google Scholar] [CrossRef]
- Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis. J. Hematol. Oncol. 2018, 11, 125. [Google Scholar] [CrossRef]
- Hu, C.-M.J.; Fang, R.H.; Wang, K.-C.; Luk, B.T.; Thamphiwatana, S.; Dehaini, D.; Nguyen, P.; Angsantikul, P.; Wen, C.H.; Kroll, A.V.; et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015, 526, 118–121. [Google Scholar] [CrossRef]
- Cuiffo, B.G.; Karnoub, A.E. Mesenchymal stem cells in tumor development: Emerging roles and concepts. Cell Adh. Migr. 2012, 6, 220–230. [Google Scholar] [CrossRef]
- Lee, M.; Jeong, S.Y.; Ha, J.; Kim, M.; Jin, H.J.; Kwon, S.-J.; Chang, J.W.; Choi, S.J.; Oh, W.; Yang, Y.S. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2014, 446, 983–989. [Google Scholar] [CrossRef]
- Wang, X.; Chen, H.; Zeng, X.; Guo, W.; Jin, Y.; Wang, S.; Tian, R.; Han, Y.; Guo, L.; Han, J.; et al. Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system. Acta Pharm. Sin. B 2019, 9, 167–176. [Google Scholar] [CrossRef] [PubMed]
- Eggenhofer, E.; Benseler, V.; Kroemer, A.; Popp, F.; Geissler, E.; Schlitt, H.; Baan, C.; Dahlke, M.; Hoogduijn, M. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 2012, 3, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qu, N.; Sun, Y.; Li, Y.; Hao, F.; Qiu, P.; Teng, L.; Xie, J.; Gao, Y. Docetaxel-loaded human serum albumin (HSA) nanoparticles: Synthesis, characterization, and evaluation. Biomed. Eng. OnLine 2019, 18, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mahmood, M.A.; Madni, A.; Rehman, M.; Rahim, M.A.; Jabar, A. Ionically cross-linked chitosan nanoparticles for sustained delivery of docetaxel: Fabrication, post-formulation and acute oral toxicity evaluation. Int. J. Nanomed. 2019, 14, 10035. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Huang, Y.; Li, S. Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery. Aaps Pharmscitech. 2014, 15, 862–871. [Google Scholar] [CrossRef] [Green Version]
- Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J.F.W.; Hennink, W.E. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. Pharmaceuitcal Res. 2010, 27, 2569–2589. [Google Scholar] [CrossRef] [Green Version]
- Bao, Y.; Deng, Q.; Li, Y.; Zhou, S. Engineering docetaxel-loaded micelles for non-small cell lung cancer: A comparative study of microfluidic and bulk nanoparticle preparation. RSC Adv. 2018, 8, 31950–31966. [Google Scholar] [CrossRef] [Green Version]
- An, Q.; Shi, C.X.; Guo, H.; Xie, S.M.; Yang, Y.Y.; Liu, Y.N.; Liu, Z.H.; Zhou, C.Z.; Niu, F.J. Development and characterization of octreotide-modified curcumin plus docetaxel micelles for potential treatment of non-small-cell lung cancer. Pharmaceutical Dev. Technol. 2019, 24, 1164–1174. [Google Scholar] [CrossRef]
- Gong, F.; Wang, R.; Zhu, Z.; Duan, J.; Teng, X.; Cui, Z.K. Drug-interactive mPEG-b-PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel. Drug Deliv. 2020, 27, 238–247. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Chan, J.M.; Gu, F.X.; Rhee, J.W.; Wang, A.Z.; Radovic-Moreno, A.F.; Alexis, F.; Langer, R.; Farokhzad, O.C. Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano 2008, 2, 1696–1702. [Google Scholar] [CrossRef] [Green Version]
- Mukherjee, A.; Waters, A.K.; Kalyan, P.; Achrol, A.S.; Kesari, S.; Yenugonda, V.M. Lipid-Polymer Hybrid Nanoparticles as a Nextgeneration Drug Delivery Platform: State of the Art, Emerging Technologies, and Perspectives. Int. J. Nanomed. 2019, 14, 1937–1952. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, R.; Zhang, Z.; Wang, B.; Chen, G.; Zhang, Y.; Deng, H.; Tang, Z.; Mao, J.; Wang, L. Combination chemotherapy of lung cancer–co-delivery of docetaxel prodrug and cisplatin using aptamer-decorated lipid–polymer hybrid nanoparticles. Drug Des. Devel. Ther. 2020, 14, 2249–2261. [Google Scholar] [CrossRef] [PubMed]
- Song, Z.; Shi, Y.; Han, Q.; Dai, G. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles. Biomed. Pharmacother. 2018, 105, 18–26. [Google Scholar] [CrossRef]
- Greenhalgh, J.; Dwan, K.; Boland, A.; Bates, V.; Vecchio, F.; Dundar, Y.; Jain, P.; Green, J.A. First-Line Treatment of Advanced Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Squamous Non-Small Cell Lung Cancer. Cochrane Database Syst. Rev. 2016, 25, CD010383. [Google Scholar] [CrossRef]
- Wang, N.; Fung, K.K.; Lu, W.; Yang, S. Structural characterization of carbon nanotubes and nanoparticles by high-resolution electron microscopy. Chem. Phys. Lett. 1994, 229, 587–592. [Google Scholar] [CrossRef]
- Grobert, N. Carbon Nanotubes-Becoming Clean. Mater. Today 2007, 10, 28–35. [Google Scholar] [CrossRef]
- Marchesan, S.; Kostarelos, K.; Bianco, A.; Prato, M. The winding road for carbon nanotubes in nanomedicine. Mater. Today 2015, 18, 12–19. [Google Scholar] [CrossRef]
- Chen, Z.; Wu, W.; Chen, Z.; Cong, X.; Qiu, J. Microstructural characterization on ZrC doped carbon/carbon composites. Ceram. Int. 2012, 38, 761–767. [Google Scholar] [CrossRef]
- Elhissi, A.; Ahmed, W.; Dhanak, V.R.; Subramani, K. Carbon Nanotubes in Cancer Therapy and Drug Delivery. J. Drug Deliv. 2012, 2012, 837327. [Google Scholar] [CrossRef]
- Datir, S.R.; Das, M.; Singh, R.P.; Jain, S. Hyaluronate tethered, “smart” multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin. Bioconjugate Chem. 2012, 23, 2201–2213. [Google Scholar] [CrossRef]
- Das, M.; Datir, S.R.; Singh, R.P.; Jain, S. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic acid-multiwalled carbon nanotube conjugate. Mol. Pharm. 2013, 10, 2543–2557. [Google Scholar] [CrossRef] [PubMed]
- Arya, N.; Arora, A.; Vasu, K.S.; Sood, A.K.; Katti, D.S. Combination of single walled carbon nanotubes/graphene oxide with paclitaxel: A reactive oxygen species mediated synergism for treatment of lung cancer. Nanoscale 2013, 5, 2818–2829. [Google Scholar] [CrossRef]
- Moore, T.L.; Pitzer, J.E.; Podila, R.; Wang, X.; Lewis, R.L.; Grimes, S.W.; Wilson, J.R.; Skjervold, E.; Brown, J.M.; Rao, A.; et al. Multifunctional polymer-coated carbon nanotubes for safe drug delivery. Part. Part. Syst. Charact. 2013, 30, 365–373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fabbro, C.; Ali-Boucetta, H.; Ros, T.D.; Kostarelos, K.; Bianco, A.; Prato, M. Targeting carbon nanotubes against cancer. Chem. Commun. 2012, 48, 3911–3926. [Google Scholar] [CrossRef]
- Singh, R.P.; Sharma, G.; Singh, S.; Patne, S.C.; Pandey, B.L.; Koch, B.; Muthu, M.S. Effects of transferrin conjugated multi-walled carbon nanotubes in lung cancer delivery. Mater. Sci. Eng. C 2016, 67, 313–325. [Google Scholar] [CrossRef]
- Li, B.; Zhang, X.X.; Huang, H.Y.; Chen, L.Q.; Cui, J.H.; Liu, Y.; Jin, H.; Lee, B.J.; Cao, Q.R. Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel. Int. J. Pharm. 2018, 543, 8–20. [Google Scholar] [CrossRef]
- He, Q.; Shi, J. Mesoporous silica nanoparticle based nano drug delivery systems: Synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem. 2011, 21, 5845–5855. [Google Scholar] [CrossRef]
- Slowing, I.I.; Vivero-Escoto, J.L.; Wu, C.W.; Lin, V.S.Y. Mesoporous Silica Nanoparticles as Controlled Release Drug Delivery and Gene Transfection Carriers. Adv. Drug Deliv. Rev. 2008, 60, 1278–1288. [Google Scholar] [CrossRef]
- Wang, Y.; Zhao, Q.; Han, N.; Bai, L.; Li, J.; Liu, J.; Che, E.; Hu, L.; Zhang, Q.; Jiang, T.; et al. Mesoporous Silica Nanoparticles in Drug Delivery and Biomedical Applications. Nanomedicine 2015, 11, 313–327. [Google Scholar] [CrossRef]
- Rosenholm, J.; Sahlgren, C.; Lindén, M. Cancer-cell targeting and cell-specific delivery by mesoporous silica nanoparticles. J. Mater. Chem. 2010, 20, 2707–2713. [Google Scholar] [CrossRef]
- Dilnawaz, F.; Sahoo, S.K. Augmented Anticancer Efficacy by si-RNA Complexed Drug-Loaded Mesoporous Silica Nanoparticles in Lung Cancer Therapy. ACS Appl. Nano Mater. 2018, 1, 730–740. [Google Scholar] [CrossRef]
- Van Rijt, S.; Bölükbas, D.; Argyo, C.; Datz, S.; Lindner, M.; Eickelberg, O.; Königshoff, M.; Bein, T.; Meiners, S. Protease Mediated Release of Chemotherapeutics From Mesoporous Silica Nanoparticles to Ex Vivo Human and Mouse Lung Tumors. ACS Nano 2015, 9, 2377–2389. [Google Scholar] [CrossRef] [PubMed]
- Makhsin, R.S.; Razak, K.A.; Zakaria, N.D.; Noorhashimah, M.N. Gold nanoparticles for diagnostic development. In Sustainable Diagnostics for Low Resource Areas; Penerbit Universiti Sains Malaysia: Penang, Malaysia, 2019. [Google Scholar]
- Ahmad, M.Z.; Akhter, S.; Rahman, Z.; Akhter, S.; Anwar, M.; Mallik, N.; Ahmad, F.J. Nanometric Gold in Cancer Nanotechnology: Current Status and Future Prospect. J. Pharm. Pharmacol. 2013, 65, 634–651. [Google Scholar] [CrossRef] [PubMed]
- Dykman, L.; Khlebtsov, N. Gold nanoparticles in biomedical applications: Recent advances and perspectives. Chem. Soc. Rev. 2012, 41, 2256–2282. [Google Scholar] [CrossRef]
- De Jong, W.H.; Borm, P.J.A. Drug Delivery and Nanoparticles: Applications and Hazard. Int. J. Nanomed. 2008, 3, 133–149. [Google Scholar] [CrossRef] [Green Version]
- Xie, H.; Gu, S.; Zhang, J.; Hu, Q.; Yu, X.; Kong, J. Novel PEI–AuNPs–Mn III PPIX nanocomposite with enhanced peroxidase-like catalytic activity in aqueous media. Comptes. Rendus Chim. 2018, 21, 104–111. [Google Scholar] [CrossRef]
- Dreaden, E.C.; Austin, L.A.; Mackey, M.A.; El-Sayed, M.A. Size matters: Gold nanoparticles in targeted cancer drug delivery. Ther. Deliv. 2012, 3, 457–478. [Google Scholar] [CrossRef] [Green Version]
- Thambiraj, S.; Shruthi, S.; Vijayalakshmi, R.; Ravi Shankaran, D. Evaluation of cytotoxic activity of docetaxel loaded gold nanoparticles for lung cancer drug delivery. Cancer Treat. Res. Commun. 2019, 21, 100157. [Google Scholar] [CrossRef]
- Beik, J.; Khateri, M.; Khosravi, Z.; Kamrava, S.K.; Kooranifar, S.; Ghaznavi, H.; Shakeri-Zadeh, A. Gold nanoparticles in combinatorial cancer therapy strategies. Coord. Chem. Rev. 2019, 387, 299–324. [Google Scholar] [CrossRef]
- Kumar, S.; Diwan, A.; Singh, P.; Gulati, S.; Choudhary, D.; Mongia, A.; Shukla, S.; Gupta, A. Functionalized gold nanostructures: Promising gene delivery vehicles in cancer treatment. RSC Adv. 2019, 9, 23894–23907. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
A. Razak, S.A.; Mohd Gazzali, A.; Fisol, F.A.; M. Abdulbaqi, I.; Parumasivam, T.; Mohtar, N.; A. Wahab, H. Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview. Cancers 2021, 13, 400. https://doi.org/10.3390/cancers13030400
A. Razak SA, Mohd Gazzali A, Fisol FA, M. Abdulbaqi I, Parumasivam T, Mohtar N, A. Wahab H. Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview. Cancers. 2021; 13(3):400. https://doi.org/10.3390/cancers13030400
Chicago/Turabian StyleA. Razak, S. Aishah, Amirah Mohd Gazzali, Faisalina Ahmad Fisol, Ibrahim M. Abdulbaqi, Thaigarajan Parumasivam, Noratiqah Mohtar, and Habibah A. Wahab. 2021. "Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview" Cancers 13, no. 3: 400. https://doi.org/10.3390/cancers13030400